YEREVAN (Noyan Tapan)–Two drugs–"Pozikor" produced by the Roche company and "Raxar" produced by the Glaxo Welcome company–are currently being withdrawn from Armenia’s medicine market. Talking to Noyan Tapan–Deputy Director of the National Drug Agency Hran’sh Nikoghossian said that the firms themselves made decisions on recalling the medicines from the market because of their undesirable side-effects and addressed letters to the countries where the medicines were registered.
Nikoghossian explained that the Agency conducts post-marketing studies of medicines after their registration. As a result of these studies certain medicines can be withdrawn from the registration list. The same applies to firms. Thus–during the last year the Agency rejected as low-quality several groups of medicines produced by one of the firms and raised the question of the advisability of the firm’s presence in the Armenian medicine market. Since then the firm has monitored its supplies and no claims are currently made against it. Last year alone the Agency denied registration to over 30 medicines from different countries. There are also rejections during the import of registered medicines to the country. Thus–during the last month five many medicines were denied import because of being of low quality. Inspections of medical establishmen’s and drugstores conducted by the inspection bodies show that these medicines used or sold there meet the requiremen’s–and the rejected ones did not appear on the market. Replicas appear on the Armenian market more and more rarely.
Pharmacologists are concerned that medicines that are being withdrawn from the Western markets are still sold in Armenia. Among them are–in particular–medicines of Russian make which are relatively cheap such as "Analgin,"Streptocit," and "Levomitecin."
The number of medicines registered in Armenia currently totals 2,500. They are supplied by 200 firms from 40 countries–Hungary being the leader.
Armenia also supplies the market with about 100 types of domestically produced medicines.